Cardioprotective effect of erythropoietin preparations in patients with chronic renal failure


Cite item

Full Text

Abstract

Aim. To investigate effects of early correction of anemia on the rate of cardiovascular complications
and survival on regular hemodialysis (RHD).
Material and methods. Eighty patients with chronic renal failure (CRF) on regular hemodialysis entered two groups: group 1 with hemoglobin (Hb) < 80 g/l (n = 36) and group 2 with Hb > 100 g/l
(п = 44). 90% patients of group 2 were treated for renal anemia for 6-8 months ofpreanalysis CRF.
When placed on RHD, group 1 started therapy with epoetin, 39 patients of group 2 continued epoetin
treatment.
Results. Patients of group 2 had a higher rate of eccentric left ventricular hypertrophy (LVH) with reduced ejection fraction and development of congestive cardiac failure and coronary heart disease. Eccentric L VH in group 1 patients regressed only in 80% when the patients were on hemodialysis and received epoetin for correction of anemia. Overall cardiac death in group 1 was twice that of group 2 patients.
Conclusion. Early correction of anemia led to a 50% increase in 5-year survival. This fact can be explained with inhibited progression of eccentric LVH.

References

  1. Eckardt R. U. Cardiovascular consequences of renal anaemia and erythropoietin therapy. Nephrol. Dial. Transplant. 1999; 14: 1317-1323.
  2. Ермоленко В. М., Иващенко М. А. Уремия и эритропоэтин. М; 1999.
  3. London G. M., Guerin A. P. et al. Cardiac and arterial interactions in ESRD. Kidney Int. 1996; 50: 600-608.
  4. Levin A., Thompson C. R. et al. Left ventricular mass index increase in early renal disease: impact of decline in Hb. Am. J. Kidney Dis. 1999; 34: 125-134.
  5. Amann K., Ritz E. Microvascular disease - the Cinderella of uraemic heart disease. Nephrol. Dial. Transplant. 2000; 15: 1493-1503.
  6. Eknoyan G. Cardiovascular mortality and morbidity in dialysis patients. Miner. Electrolyte Metab. 1999; 25: 100-104.
  7. Foley R. N., Parfrey P. S., Harnett J. D. et al. The impact of anemia on cardiomyopathy, morbidity and mortality in ESRD.Am. J. Kidney Dis. 1996; 28: 53-61.
  8. Locatelly F., Conte F., Marcelli D. et al. The impact of hematocrit level and erythropoietin treatment on overall and cardiovascular mortality and morbidity - the experience of Lombardy dialysis registry. Nephrol. Dial. Transplant. 1998; 13: 1642-1644.
  9. Furuland H, Linde Т., Ahlmen J. et al. A randomized controlled trial of Hb normalisation with epoetin alfa in predialysis patients. Nephrol. Dial. Tranplant. 2003; 18: 353-361.
  10. Silberberg J. C, Racine N., Bane P. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with rhEPO. Can. J. Cardiol. 1990; 6: 1-4.
  11. Алексеева Т. Б., Николаев А. Ю., Дасаева Л. А. Препараты эритропоэтина у больных хронической почечной недостаточностью в стадии консервативного лечения. Тер. арх. 2000; 6: 58-63.
  12. Portoles J., Torralbo A., Martin P. et al. Cardiovascular effects of rhEPO in predialysis patients. Am. J. Kidney Dis. 1997; 29: 541-548.
  13. Kausz А. Т., Obrador G. Т., Pereira B. J. Anemia management in patients with chronic renal insufficiency. Am. J. Kidney Dis. 2000; 36 (suppl. 3): 39-51.
  14. Valderrabano F. Correction of anemia with rhEPO prevent of LV hypertrophy in predialysis patients. J. Am. Soc. Nephrol. 2000; ll:abstr. 0424.
  15. Roth D., Smith R., Schulman G. et al. Effect of rhEPO on renal function in predialysis patients. Am. J. Kidney Dis. 1994; 24: 777-784.
  16. US Recombinant human Erythropoietin Predialysis group: double blind placebo-controlled study. Am. J. Kidney Dis. 1991; 18: 50-59.
  17. Kuriyama S., Tomonari H., Yoshida H. et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure. Nephron 1997; 77: 176-185.
  18. Fink J. C, Blahut S. A., Reddy M. et al. Use of erythropoietin before the initiation of dialysis and its impact on mortality.Am. J. Kidney Dis. 2001; 37: 348-355.
  19. Silverberg D. S., Blum M., Agbaria Z. et al. The effect of i.v. Iron alone or in combination with low dose rhEPO in the rapid correction of anemia of predialysis patients. Clin. Nephrol. 2001; 55: 212-219.
  20. Sunder-Plassman G., Horl W. Importance of iron supply for erythropoietin therapy. Nephrol. Dial. Transplant. 1995; 10: 979-987.
  21. Николаев А. Ю., Ермоленко В. М., Лашутин С. В. Методы введения эритропоэтина больных ХПН с анемией на диализе. Практ. нефрол. 1997; 1: 14-17.
  22. Besarab A., Reyes С. М., Homberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am. J. Kidney Dis. 2002; 40: 439-446.
  23. Casadeval N., NatafJ., Viron B. et al. Pure red cell aplasia and antierythropoietin antibodies in patients treated withrhEPO. N. Engl. J. Med. 2002; 346: 469-475.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2004 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies